- Home
- DENN vs CGEN Comparison
DENN vs CGEN Comparison
Compare DENN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DENN
- CGEN
- Stock Information
- Founded
- DENN 1953
- CGEN 1993
- Country
- DENN United States
- CGEN Israel
- Employees
- DENN N/A
- CGEN N/A
- Industry
- DENN Restaurants
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DENN Consumer Discretionary
- CGEN Health Care
- Exchange
- DENN Nasdaq
- CGEN Nasdaq
- Market Cap
- DENN 203.4M
- CGEN 167.4M
- IPO Year
- DENN 1989
- CGEN 2000
- Fundamental
- Price
- DENN $3.95
- CGEN $1.54
- Analyst Decision
- DENN Strong Buy
- CGEN
- Analyst Count
- DENN 6
- CGEN 0
- Target Price
- DENN $7.46
- CGEN N/A
- AVG Volume (30 Days)
- DENN 611.8K
- CGEN 204.3K
- Earning Date
- DENN 08-04-2025
- CGEN 08-05-2025
- Dividend Yield
- DENN N/A
- CGEN N/A
- EPS Growth
- DENN N/A
- CGEN N/A
- EPS
- DENN 0.33
- CGEN N/A
- Revenue
- DENN $453,997,000.00
- CGEN $27,589,000.00
- Revenue This Year
- DENN $7.51
- CGEN N/A
- Revenue Next Year
- DENN $1.98
- CGEN $105.77
- P/E Ratio
- DENN $12.01
- CGEN N/A
- Revenue Growth
- DENN N/A
- CGEN N/A
- 52 Week Low
- DENN $2.85
- CGEN $1.13
- 52 Week High
- DENN $7.73
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- DENN 44.45
- CGEN 45.94
- Support Level
- DENN $3.80
- CGEN $1.46
- Resistance Level
- DENN $4.48
- CGEN $1.74
- Average True Range (ATR)
- DENN 0.20
- CGEN 0.09
- MACD
- DENN -0.05
- CGEN -0.02
- Stochastic Oscillator
- DENN 20.88
- CGEN 38.89
About DENN Denny's Corporation
Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.